U.S. stops distributing Lilly's COVID-19 antibody therapy in six states, instead recommends Regeneron's treatment
Dow Jones2021-05-28
MW U.S. stops distributing Lilly's COVID-19 antibody therapy in six states, instead recommends Regeneron's treatment
The U.S. government said this week it is halting distribution of Eli Lilly & Co.'s $(LLY)$ COVID-19 antibody treatment in six states due to the growing prevalence of the P.1 and B.1.351 variants there. Lilly's combination therapy of bamlanivimab and etesevimab "are not active against either the P.1 or B.1.351 variants," which were first identified in Brazil and South Africa, respectively, the Assistant Secretary for Preparedness and Response said Wednesday .
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
